Eohilia (budesonide oral suspension − Takeda) — Cigna

Eosinophilic esophagitis

Initial criteria

Patient age ≥ 11 years; AND
Diagnosis of eosinophilic esophagitis confirmed by endoscopic biopsy demonstrating ≥ 15 intraepithelial eosinophils per high-power field; AND
Patient meets ONE of the following (i or ii): i) Patient has received at least 8 weeks of therapy with a proton pump inhibitor; OR ii) According to the prescriber, the patient has severe disease with esophageal stricture; AND
Patient meets ONE of the following (i or ii): i) Patient has tried dietary modifications to manage eosinophilic esophagitis; OR ii) The prescriber has determined that the patient is not an appropriate candidate for dietary modifications; AND
Patient meets ONE of the following (i or ii): i) Patient is currently receiving a course of Eohilia, and additional medication is needed to complete a 12‑week course of treatment; OR ii) Patient meets ONE of the following (a or b): a) Patient has not been treated with Eohilia within the previous 6 months; OR b) According to the prescriber, the patient is experiencing recurrent worsening dysphagia after discontinuing Eohilia therapy; AND
Medication is prescribed by or in consultation with an allergist or gastroenterologist

12 weeks